Compare Progressive Corp (PGR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Zimmer Biomet Holdings Inc — how do they compare? Progressive Corp trades at $218.9 (market cap $126.95B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Progressive Corp is far larger — about 7.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PGR | ZBH | |
|---|---|---|
Market Cap | $126.95B | $16.95B |
Volume | 2,749,438 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $242.16 | $103.98 |
52-Week Low | $190.40 | $79.58 |
Typical Hold Time | 81 Days | 89 Days |
Enterprise Value | $135.16B | $24.02B |
Dividend Yield | 0.18% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook. The stock shows strong fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Valuation metrics appear reasonable with P/E of 10.74 and ROE of 34.94%. Recent earnings beat expectations in Q2 2026, and analyst consensus targets $222.23.
PGR presents a compelling investment case with consistent revenue growth and strong profitability. However, investors face risks from intensifying auto insurance competition and potential margin pressure. The stock's current price near resistance levels suggests limited near-term upside despite positive analyst sentiment.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
